NICE Review

Deltex Medical Group PLC
14 February 2006



                            Deltex Medical Group plc


              NICE assesses CardioQ as standard clinical practice



Tuesday 14 February 2006: Deltex Medical Group plc ('Deltex Medical' or the
'Company'), the AIM listed haemodynamic monitoring company, today announces the
results of a NICE ('National Institute of Clinical Excellence') review of the
technique of oesophageal Doppler monitoring ('ODM').


NICE's review concluded that the CardioQ does not require further approval by
NICE.  NICE has confirmed that 'oesophageal Doppler monitoring is considered
standard clinical practice.'


The NICE review, under its Interventional Procedures Programme, involved
consultation with clinical experts nominated by the Association of Anaesthetists
of Great Britain and Ireland and the Intensive Care Society.  The review also
included a study of the extensive body of published clinical evidence on the
technique of ODM.  The vast majority of clinical data on ODM comprises studies
which used the Company's CardioQ monitors or predecessor devices.


NICE is the UK government department responsible for assessing the safety and
efficacy of new medical technologies under its Interventional Procedures
Programme.  If NICE concludes that a new technology falls within its remit under
the Interventional Procedures Programme, it will go on to develop guidance on
the safety and efficacy of that procedure.


The development of such guidance can take a considerable amount of time,
especially as NICE has an extensive backlog of cases to review.  NICE can
require that every doctor using a new technology in the NHS records and reports
its every use during the review process.  During the NICE review process NHS
Trusts may prefer not to purchase the technology under review pending
publication of the results of the NICE evaluation.


Nigel Keen, Deltex Medical's Chairman, commented:


'NICE's acknowledgment that use of the CardioQ is considered to be a standard
clinical practice in the UK NHS is a significant step forward for the Company,
as it gives the doctors seeking to purchase our products additional support when
making purchasing requests from the hospital finance managers.


'Oesophageal Doppler monitoring is the only cardiac output monitoring technology
to have been assessed as standard clinical practice by NICE.  This further
differentiates our products which are safer and more efficacious than
traditional and alternative technologies as well as being more effective
clinically, better evidenced and less expensive.'



For further information, please contact:-


Deltex Medical Group plc
01243 774 837

Nigel Keen, Chairman                               [e-mail]
Andy Hill, Chief                                    [e-mail]
Executive
Ewan Phillips,                                  [e-mail]
Finance Director



Financial Dynamics
0207 831 3113

David Yates                                                  [e-mail]
John Gilbert                                                [e-mail]

Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.



                      This information is provided by RNS
            The company news service from the London Stock Exchange